A part of Watch Media

MedWatchFriday27 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
07/05/2021at 15:36

EU splits on vaccine patent waivers to cast doubt on US plan

Spain has backed a US proposal to waive intellectual property rights for coronavirus vaccines, breaking ranks with Germany and complicating efforts by the European Union to form a common stance.
Photo: MANDEL NGAN/AFP / AFP
BY NIKOS CHRYSOLORAS AND RODRIGO ORIHUELA, BLOOMBERG

"Intellectual property cannot be an obstacle to ending Covid-19 and to ensuring equitable and universal access to vaccines," the Spanish government said in an informal policy paper circulated Thursday evening. Its view is that consensus must be "urgently found on the proposal for a temporary waiver."

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: FRED TANNEAU/AFP / AFP

    Pfizer and Biontech request to expand authorization for vaccine for adolescents

    For subscribers

  • Photo: Joachim Ladefoged/JPA

    Danish government will allow gradual vaccine production in Denmark

    For subscribers

  • Photo: Philip Davali/Ekstra Bladet, Philip Davali

    Bavarian Nordic on vaccine candidate: Preclinical data indicates broad protection

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Photo: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
  • AGC's Japanese and Danish factories to produce German biotech firm's drug candidate
  • AGC Biologics breaks ground on USD 190m Danish factory

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Photo: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

For subscribers

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Photo: Phillips-medisize
Medtech

US medtech group expands production in Denmark

For subscribers

Per Wold-Olsen, outgoing chairman of GN's board | Photo: Mik Eskestad
Hearing health

GN's veteran chairman to retire

For subscribers

Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Foto: Mc2 Therapeutics / Pr
Pharma & biotech

MC2 Therapeutics CEO steps down as board member

For subscribers

Foto: Sebastian Kahnert/AP/Ritzau Scanpix
Pharma & biotech

Atrogi doses first patient in diabetes study

For subscribers

Further reading

Photo: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Photo: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

An analyst reacts to the news that GN’s chair is not seeking re-election this year – ”he has been key in helping GN secure a significant position on the hearing aid market.”

For subscribers

Latest news

  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
  • US medtech group expands production in Denmark – 26 Jan
  • GN's veteran chairman to retire – 26 Jan
  • MC2 Therapeutics CEO steps down as board member – 26 Jan
  • Atrogi doses first patient in diabetes study – 26 Jan
  • FDA approves ALK's house dust mite tablet for teens – 25 Jan
  • Bavarian Nordic featured on Cowen list of 2023 biotech favorites – 25 Jan
  • Biontech inks deal with UK on sped-up cancer trials – 25 Jan
  • FDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccine – 25 Jan
See all

Jobs

  • Commercial Director

  • Clinical Operational Associate

  • Principal Laboratory Technologist

  • Head of Regulatory Affairs Danmark

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Head of International Sales

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Senior Regulatory Affairs Professional

See all jobs

Jobs

  • Commercial Director

  • Clinical Operational Associate

  • Principal Laboratory Technologist

  • Head of Regulatory Affairs Danmark

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Head of International Sales

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Senior Regulatory Affairs Professional

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge